article thumbnail

Progress in Dermatology Paves the Way for Vaccine Development

Drug Topics

1 “In line with the goals of its Immunization Agenda 2030, WHO has identified a new list of 17 high-priority global endemic pathogens for vaccine research and development, of which skin pathogens account for at least 8, reinforcing the need for continued focus in this area.”

Vaccines 449
article thumbnail

UK £62 billion behind in R&D global investment share, report reveals

European Pharmaceutical Review

The report suggested health research is a key area for R&D investment to align activity with broader social goals, communicate a clear strategic direction and improve R&D funding by crowding novel investment. . percent of GDP by 2030, to level with R&D investment in Sweden, the US and Taiwan. billion over a decade.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Eli Lilly to help fund cold chain initiative

European Pharmaceutical Review

.” “Efforts to expand access to medicines, especially insulin, are only beneficial when effective cold chain systems are in place to keep them at the right temperature on their way to patients,” commented Leigh Ann Pusey, Executive Vice President of corporate affairs and communications for Lilly.

article thumbnail

Navigating the regulatory challenge of PFAS for pharmaceutical manufacturers

European Pharmaceutical Review

In the EU, a joint PFAS Restriction Proposal under REACH was submitted, aiming for a full ban by 2028/2030. The PFAS regulatory challenge As a result, in the EU, a joint PFAS Restriction Proposal under REACH was submitted in 2023, aiming for a full ban on all PFAS by 2028/2030. There is worldwide concern around the use of PFAS.

article thumbnail

Lilly and EVA Pharma to aid affordable insulin access in Africa

European Pharmaceutical Review

Lilly’s 30×30 initiative aims to improve access to quality healthcare for 30 million people living in limited-resource settings, annually, by 2030. Communication with WHO encourage implementation of and accountability for the commitments and contributions toward improving access to insulin.

article thumbnail

BioNTech and UK Government announce strategic partnership to provide mRNA cancer immunotherapies

Pharmafile

It is hoped this acceleration will lead to up to 10,000 patients receiving such therapies by the end of 2030. German biotech company BioNTech and the UK Government have signed a Memorandum of Understanding (MoU) which will accelerate clinical trials of personalised mRNA immunotherapies. read more.

article thumbnail

Lilly preps for rollout of its connected diabetes system

pharmaphorum

The reusable Smart Button attaches to the top of the Tempo insulin pen, and communicates via Bluetooth with the app – a bespoke version of Welldoc’s BlueStar software – to log when shots are administered and the dose taken. billion in 2020 to more than $16 billion by 2030, according to GlobalData. The system works as follows.